Detalhe da pesquisa
1.
A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma.
Blood
; 120(9): 1801-9, 2012 Aug 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-22665938
2.
Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma.
Blood
; 118(7): 1763-5, 2011 Aug 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-21673347
3.
Long-term results of single-agent thalidomide as initial therapy for asymptomatic (smoldering or indolent) myeloma.
Am J Hematol
; 85(10): 737-40, 2010 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-20730790
4.
Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs.
Am J Hematol
; 85(10): 757-9, 2010 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-20872958
5.
Carfilzomib, lenalidomide, and low-dose dexamethasone in elderly patients with newly diagnosed multiple myeloma.
Haematologica
; 99(9): e162-4, 2014 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-24972772